Fate Therapeutics, Inc. (FATE) financial statements (2022 and earlier)

Company profile

Business Address 12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO, CA 92131
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments134167100191899265
Cash and cash equivalents134167100191898965
Short-term investments     4 
Receivables96 1   
Other undisclosed current assets491321127141411
Total current assets:6334942272051039366
Noncurrent Assets
Operating lease, right-of-use asset716723
Property, plant and equipment9232115322
Long-term investments and receivables101 39    
Long-term investments101 39    
Contract with customer, asset, net101412
Restricted cash and investments151500000
Other noncurrent assets0001000
Total noncurrent assets:288128758322
TOTAL ASSETS:9216223022131059568
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities51222115953
Accounts payable9664211
Accrued liabilities42161511742
Deferred revenue21213
Debt  22 88
Deferred revenue and credits222
Contract with customer, liability8
Other undisclosed current liabilities94332  0
Total current liabilities:81862827111513
Noncurrent Liabilities
Long-term debt and lease obligation10994251215311
Long-term debt, excluding current maturities   1215311
Operating lease, liability1099425
Liabilities, other than long-term debt2746411246
Deferred revenue and credits235
Accounts payable and accrued liabilities   1011
Deferred revenue27464
Contract with customer, liability8
Deferred rent credit   3
Total noncurrent liabilities:136140292417716
Total liabilities:2182265751282230
Stockholders' equity
Stockholders' equity attributable to parent679384245160777338
Preferred stock000000 
Common stock0000000
Additional paid in capital1,449941628446296249180
Accumulated other comprehensive income (loss)(1)00(0)(0)(0) 
Accumulated deficit(769)(557)(384)(285)(219)(176)(142)
Total stockholders' equity:679384245160777338
Other undisclosed liabilities and equity251211   
TOTAL LIABILITIES AND EQUITY:9216223022131059568

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues5631115442
Revenue, net442
Gross profit:5631115442
Operating expenses(273)(160)(111)(72)(46)(36)(30)
Operating loss:(217)(128)(101)(67)(42)(32)(28)
Nonoperating income (expense)6(43)31(1)(1)(2)
Investment income, nonoperating12 0   
Other nonoperating income (expense)5(45)30(1)(1)(2)
Interest and debt expense  (2)(2)(0)(2)(2)
Loss before gain (loss) on sale of properties:(211)(171)(100)(68)(43)(35)(32)
Other undisclosed net income (loss)(1)(2)21   
Net loss:(212)(173)(98)(67)(43)(35)(32)
Other undisclosed net income attributable to parent    022
Net loss available to common stockholders, diluted:(212)(173)(98)(67)(43)(33)(30)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(212)(173)(98)(67)(43)(35)(32)
Other undisclosed comprehensive income (loss)(1)00002 
Comprehensive loss, net of tax, attributable to parent:(213)(173)(98)(67)(43)(33)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: